Canbex Therapeutics has started a Phase I clinical trial of its novel, orally active lead compound VSN16R for treatment of spasticity in people with multiple sclerosis.
The placebo-controlled, single ascending dose and multiple ascending dose design study is aimed at evaluating the safety and tolerability of VSN16R in humans.
Go deeper with GlobalData
A total of 72 healthy volunteers will be enrolled in the first-in-man trial, which is being conducted by a US-based clinical research organisation Quintiles.
Spasticity is characterised by sudden and uncontrollable movements of limb and torso musculature, and is among the most painful, damaging and debilitating symptoms of multiple sclerosis.
Many patients cannot tolerate current drug treatments, which have a high- level of undesirable side effects, particularly sedation and cognitive dysfunction, so they are treated with palliative measures alone, or with drug regimes that result in poor quality of life, the company said.
See Also:
Canbex chief executive officer Jesse Schulman said the advancement of VSN16R to first dose in a patient marked a milestone.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"After years of highly promising preclinical research, we believe that VSN16R has the potential to become an important advance in the treatment of spasticity, a condition for which there remains a substantial unmet medical need," Schulman said.
The Phase I trial was initiated following positive results from preclinical studies that showed the excellent safety, efficacy and tolerability of VSN16R.
In preclinical studies, VSN16R was very well-tolerated and did not induce the adverse behavioural responses such as hypomotility, associated with CNS-active cannabinoids and baclofen.
VSN16R, which is administered orally, is a water-soluble compound that produces vasorelaxation through a non-CB1, non-CB2 cannabinoid receptors.
The drug candidate controls the spasticity by targeting cannabinoid receptors within the periphery.
Image: Photomicrograph of a demyelinating MS-Lesion. Photo: courtesy of Marvin 101.
